Skip to content

Released Mar 9, 2023, before the open

10-K filed Mar 9, 2023, 68 days after period end · 0001628280-23-007266

Q4 2022 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$39.28MderivedN/M vs Q4 2021N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$38,686,000—
Operating Cash Flowderived-$30,713,000N/M
Free Cash Flowderived-$35,527,000N/M

What the release said

The release

Same quarter

MetricQ4 2022derived from reported figuresQ4 2021derived from reported figures
Net Income-$39.28M-$62.91M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR